Search for: "Astrazeneca" Results 301 - 320 of 1,244
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
3 May 2017, 9:59 pm by Patent Docs
InnoPharma Licensing, LLC v AstraZeneca AB PTAB Petition: IPR2017-00900; filed February 17, 2017. [read post]
1 May 2017, 11:36 am by Howard Knopf
https://upload.wikimedia.org/wikipedia/commons/5/5a/Lilly_Strattera_60mg_Capsule.jpgAs everyone knows by now, Canada supposedly “won” the Eli Lilly NAFTA case. [read post]
1 May 2017, 11:36 am by Howard Knopf
https://upload.wikimedia.org/wikipedia/commons/5/5a/Lilly_Strattera_60mg_Capsule.jpgAs everyone knows by now, Canada supposedly “won” the Eli Lilly NAFTA case. [read post]
29 Apr 2017, 10:08 am by Dr. Shezad Malik
Wrendell Chester, from Texas, recently filed a personal injury and product liability lawsuit, against Bristol-Myers Squibb and AstraZeneca, the manufacturers of the drug. [read post]
21 Apr 2017, 6:21 am by Laurence Hooper
AstraZeneca Biopharmaceuticals Inc., but also in an emphatic letter from the U.S. government, which earlier had declined to intervene in the case. [read post]
21 Apr 2017, 4:21 am by Anders Valentin
Anders ValentinOn 17 June 2016 the Maritime and Commercial court declared AstraZeneca’s patent DK/EP 0 907 364 invalid, rendering the preliminary injunctions granted against Teva and a number of other competitors void as a result. [read post]
6 Apr 2017, 9:59 pm by Patent Docs
AstraZeneca AB PTAB Petition: IPR2017-00631; filed January 9, 2017. [read post]
8 Mar 2017, 12:37 pm by Tom Lamb
These relatively new diabetes drugs are from AstraZeneca Pharmaceuticals and were initially approved in 2014 by the FDA. [read post]
6 Mar 2017, 10:01 am by David Jensen
“Our chief scientific officer is a former MedImmune/AstraZeneca plc (ADR) (NYSE: AZN) director. [read post]
28 Feb 2017, 7:39 am by Dennis Crouch
 The particular claims require “a continuous long term regimen . . . at a dosage up to 1.5 mg/kg/day for not less than 45 days” for treating “an individual with … penile tunical fibrosis …” On anticipation, the court drew a fine-line with its closest case being AstraZeneca LP v. [read post]
27 Jan 2017, 12:00 pm by Briskman Briskman Greenberg
George Mullen brought the complaint against Nexium manufacturer AstraZeneca Pharmaceuticals in the U.S. [read post]
26 Jan 2017, 2:14 am by Alex Berry, contributor
Magic circle firm recruits David Shen in China following string of IP hires in London [read post]
25 Jan 2017, 10:48 pm
Like AIPPI's final talk of 2016, the AmeriKat is alsobristling - but instead of patent law issues, she is bristling having spotted someone wearing socks with sandalsRight before the Christmas holidays, the UK Group of AIPPI held the annual session devoted to reviewing the year's patent cases. [read post]
23 Jan 2017, 2:15 pm by Daily Record Staff
Bahija Jallal, PhD, an executive vice president with AstraZeneca and head of Gaithersburg-based MedImmune, was named 2017 Woman of the Year by The Healthcare Businesswomen’s Association. [read post]
10 Jan 2017, 8:38 am by Altman & Altman
The popular heartburn medication Nexium, released by pharmaceutical giant AstraZeneca in 2001, has been used by millions around the globe to treat their chronic heartburn with relatively few side effects. [read post]
6 Jan 2017, 7:30 am by Altman & Altman
AstraZeneca has been sued over the past decade for negligence, fraud, negligent misrepresentation, and product defects. [read post]
2 Jan 2017, 12:00 pm by Tom Lamb
Now, the PRAC's review will include the other SGLT2 inhibitor medicines dapagliflozin (Farxiga, Xigduo XR, AstraZeneca), and empagliflozin (Jardiance, Boehringer Ingelheim), based on the determination that the potential risk may be relevant for them as well. [read post]
28 Dec 2016, 7:23 am by Robert Kraft
” Judge Moss “ruled that AstraZeneca was not likely to win a lawsuit claiming it should get seven more years of exclusive rights to the drug thanks to its recent approval to treat a rare pediatric illness. [read post]
15 Dec 2016, 11:20 am by Tom Lamb
Evans predicted that doctors would now favor Jardiance for new patients over other similar drugs called SGLT-2 inhibitors, including Johnson & Johnson's Invokana and AstraZeneca's Farxiga, until they complete their own heart-protection studies in the next two years. [read post]